BRII BIOSCIENCES LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1 HKD | 0.00% |
|
+8.70% | -56.14% |
| Mar. 25 | Transcript : Brii Biosciences Limited, 2023 Earnings Call, Mar 25, 2024 | |
| Mar. 22 | Brii Biosciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2023 | 417M 57.51M 450M | Sales 2024 * | - | Capitalization | 675M 93.15M 729M |
|---|---|---|---|---|---|
| Net income 2023 | -175M -24.15M -189M | Net income 2024 * | -528M -72.86M -570M | EV / Sales 2023 | 2.46 x |
| Net cash position 2023 | 486M 67.14M 526M | Net cash position 2024 * | 956M 132M 1.03B | EV / Sales 2024 * | - |
| P/E ratio 2023 |
-8.63
x | P/E ratio 2024 * |
-1.42
x | Employees | 128 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 80.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on Brii Biosciences Limited
More press releases
| 1 week | +8.70% | ||
| Current month | +9.89% | ||
| 1 month | +1.01% | ||
| 3 months | -45.95% | ||
| 6 months | -55.56% | ||
| Current year | -56.14% |
1 week
0.85
1.06
1 month
0.851.06
Current year
0.852.39
1 year
0.854.33
3 years
0.8552.60
5 years
0.8552.60
10 years
0.8552.60
| Managers | Title | Age | Since |
|---|---|---|---|
Zhi Hong
CEO | Chief Executive Officer | 60 | 17-12-07 |
An Kang Li
DFI | Director of Finance/CFO | 47 | 20-08-31 |
David Margolis
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gregg Alton
BRD | Director/Board Member | 58 | 21-06-21 |
Tai Yin Yang
BRD | Director/Board Member | 70 | 22-08-31 |
Robert Nelsen
BRD | Director/Board Member | 60 | 18-06-21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.53% | 4 M€ | -27.92% | ||
| 0.00% | 4 M€ | -4.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 1 | 0.00% | 116 000 |
| 24-04-24 | 1 | +2.04% | 682,000 |
| 24-04-23 | 0.98 | -2.97% | 1,161,000 |
| 24-04-22 | 1.01 | -2.88% | 679,000 |
| 24-04-19 | 1.04 | +13.04% | 6,046,000 |
Delayed Quote Hong Kong S.E., April 24, 2024 at 11:40 pm EDT
More quotes
Brii Biosciences Ltd is a biotechnology company based in China and the United States principally engaged in developing therapies for infectious diseases. The Companyâs products are applied in infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens. The Company is also developing therapies for COVID-19 and other diseases.
Calendar
2024-06-24
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.9251
CNY
Average target price
4.303
CNY
Spread / Average Target
+365.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -56.14% | 93.15M | |
| -1.51% | 104B | |
| +3.22% | 97.42B | |
| +1.86% | 22.2B | |
| -16.53% | 21.23B | |
| -8.49% | 18.33B | |
| -42.33% | 16.35B | |
| -20.09% | 15.06B | |
| +5.47% | 13.98B | |
| +28.85% | 11.66B |
- Stock Market
- Equities
- 2137 Stock
